Clinical dermatology company, Botanix Pharmaceuticals (ASX:BOT), has announced the appointment of Dr Patricia Walker to its board of directors.
Dr Walker brings extensive experience from previous board positions with leading dermatology companies. She has over 60 publications in medical and scientific journals and a significant number of learned lectures to her credit. Dr Walker is the recipient of over two dozen academic and professional honours.
She brings a wealth of knowledge in drug development for key dermatology products, rom her engagements with Allergan, Allergan Medical Aesthetics, Inamed, and Kythera Biopharmaceuticals. Dr Walker also led the development of Botanix’s lead product, Sofdra (sofpironium) topical gel, from a preclinical asset to Phase 3 before its acquisition by Botanix.
Dr Walker previously served as Chief Medical Advisor for Botanix Pharmaceuticals through her consulting company, Walker Consulting.
Botanix Executive Chairman Vince Ippolito said, “Dr Walker has a rare and unique skill set, including both product development and business acumen, that makes her an outstanding addition to the Company’s Board. In addition to Dr Walker’s prowess at identifying and developing drug products, she contributes the insights of a working dermatologist.”